PRLD

Healthcare Biotechnology

Prelude Therapeutics Incorporated

$3.67

-0.12 -3.17% today

Price History

Not enough data

Key Stats

Market Cap

292.30M

Avg Volume

472,489

EPS

-$0.73

52W High

$6.83

52W Low

$1.15

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-6.67

P/B Ratio

2.83

P/S Ratio

13.04

EV/EBITDA

-3.78

EV/Revenue

10.88

Margins

Gross Margin 100.0%

Operating Margin (270.9%)

Net Margin (269.7%)

EBITDA Margin (287.7%)

Growth & Returns

Return on Equity

(57.7%)

Return on Assets

(27.2%)

Liquidity & Leverage

Current Ratio

4.07

Quick Ratio

3.99

Debt / Equity

0.13

Total Cash

151.76M

Total Debt

17.65M

About

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

preludetx.com